Search by Drug Name or NDC

    NDC 00006-4305-02 Renflexis 100 mg/1 Details

    Renflexis 100 mg/1

    Renflexis is a INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Merck Sharp & Dohme LLC. The primary component is INFLIXIMAB.

    Product Information

    NDC 00006-4305
    Product ID 0006-4305_fc8da8a3-76dd-4c0d-a987-236eec11b184
    Associated GPIs 52505040102120
    GCN Sequence Number 077588
    GCN Sequence Number Description infliximab-abda VIAL 100 MG INTRAVEN
    HIC3 S2J
    HIC3 Description ANTI-INFLAMMATORY TUMOR NECROSIS FACTOR INHIBITOR
    GCN 43638
    HICL Sequence Number 044432
    HICL Sequence Number Description INFLIXIMAB-ABDA
    Brand/Generic Brand
    Proprietary Name Renflexis
    Proprietary Name Suffix n/a
    Non-Proprietary Name infliximab
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
    Route INTRAVENOUS
    Active Ingredient Strength 100
    Active Ingredient Units mg/1
    Substance Name INFLIXIMAB
    Labeler Name Merck Sharp & Dohme LLC
    Pharmaceutical Class Tumor Necrosis Factor Blocker [EPC], Tumor Necrosis Factor Receptor Blocking Activity [MoA]
    DEA Schedule n/a
    Marketing Category BLA
    Application Number BLA761054
    Listing Certified Through 2024-12-31

    Package

    NDC 00006-4305-02 (00006430502)

    NDC Package Code 0006-4305-02
    Billing NDC 00006430502
    Package 1 VIAL in 1 CARTON (0006-4305-02) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL (0006-4305-01)
    Marketing Start Date 2017-07-01
    NDC Exclude Flag N
    Pricing Information N/A